Cited by 452Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment

Open access

Gong, Bing, Vitolo, Ottavio V., Trinchese, Fabrizio, Liu, Shumin, Shelanski, Michael, Arancio, Ottavio·2004·Journal of Clinical Investigation

DOI 10.1172/jci22831PMC PMC529285

Open this paper in CoChat — free account Open PDF

Abstract

Evidence suggests that Alzheimer disease (AD) begins as a disorder of synaptic function, caused in part by increased levels of amyloid beta-peptide 1-42 (Abeta42). Both synaptic and cognitive deficits are reproduced in mice double transgenic for amyloid precursor protein (AA substitution K670N,M671L) and presenilin-1 (AA substitution M146V). Here we demonstrate that brief treatment with the phosphodiesterase 4 inhibitor rolipram ameliorates deficits in both long-term potentiation (LTP) and contextual learning in the double-transgenic mice. Most importantly, this beneficial effect can be extended beyond the duration of the administration. One course of long-term systemic treatment with rolipram improves LTP and basal synaptic transmission as well as working, reference, and associative memory deficits for at least 2 months after the end of the treatment. This protective effect is possibly due to stabilization of synaptic circuitry via alterations in gene expression by activation of the cAMP-dependent protein kinase (PKA)/cAMP regulatory element-binding protein (CREB) signaling pathway that make the synapses more resistant to the insult inflicted by Abeta. Thus, agents that enhance the cAMP/PKA/CREB pathway have potential for the treatment of AD and other diseases associated with elevated Abeta42 levels.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci22831

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
Place navigation impaired in rats with hippocampal lesions
Morris, R. G. M., Garrud, P., Rawlins, J. N. P., & O'Keefe, J. (1982) · Nature · doi:10.1038/297681a0 · Cited by 6,340
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.
Phillips, R. G., & LeDoux, J. E. (1992) · Behavioral Neuroscience · doi:10.1037/0735-7044.106.2.274 · Cited by 3,292
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein
Bourtchuladze, R., Frenguelli, B., Blendy, J., Cioffi, D., Schutz, G., & Silva, A. J. (1994) · Cell · doi:10.1016/0092-8674(94)90400-6 · Cited by 1,800
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,506
Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Pérez‐Tur, J., Hutton, M., Buée, L., Harigaya, Y., Yager, D., et al. (1996) · Nature · doi:10.1038/383710a0 · Cited by 1,486

Flagged first, then by citations

Show all 60 references

Research works printed but not linked: 2

Masliah, 1995, Histol. Histopathol., 10, 509
10.1073/pnas.95.25.15020 · DOI

Sorted by citations

Items 201–300 of 452

β-Amyloid-induced cognitive dysfunction impairs glucose homeostasis by increasing insulin resistance and decreasing β-cell mass in non-diabetic and diabetic rats
Park, S., Kim, D. S., Kang, S., & Moon, N. R. (2013) · Metabolism · doi:10.1016/j.metabol.2013.08.007 · Cited by 42
“[39] Gong B, Vitolo OV, Trinchese F, et al.”
Background
CRTC1 Function During Memory Encoding Is Disrupted in Neurodegeneration
Parra‐Damas, A., Chen, M., Enríquez-Barreto, L., Ortega, L., Acosta, S. P., Camats‐Perna, J., Fullana, M. N., Aguilera, J., Rodrı́guez-Álvarez, J., & Saura, C. A. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.06.025 · Cited by 49
“Pharmacological activation of CREB signaling has been useful to reverse memory and synaptic deficits in AD mice (69-71).”
Roflumilast Reduces Cerebral Inflammation in a Rat Model of Experimental Subarachnoid Hemorrhage
Wu, Q., Qi, L., Li, H., Mao, L., Yang, M., Xie, R., Yang, X., Wang, J., Zhang, Z., Kong, J., et al. (2017) · Inflammation · doi:10.1007/s10753-017-0567-8 · Cited by 42
“Inhibition of PDE-4 yields beneficial effects in animal models of neurological diseases and injuries where inflammation plays an essential role, such as spinal cord injury [9], traumatic brain injury [10], Alzheimer’s disease [11], major depressive disorder [12], multiple sclerosis [13], and ischemic stroke [14, 15].”
Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease
Chiu, M., & Fan, L. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s45143 · Cited by 41
“inibitors have been proven to reverse memory impairments via synapse remolding or prevention of Aβ aggregation.(73,74) The administration of PDE3 inhibitors has proven efficacious in counteracting Aβ-induced alterations of the expression of phosphorylated CREB.”
Background
Sub-chronic rolipram treatment leads to a persistent improvement in long-term object memory in rats
Rutten, K., Prickaerts, J., Schänzle, G., Rosenbrock, H., & Blokland, A. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.04.016 · Cited by 41
“Two previous studies showed that (sub) chronic rolipram treatment improved fear conditioning in rats and spatial memory in mice (Gong et al., 2004; Monti, Berteotti, & Contestabile, 2006).”
BackgroundResultInfluential
IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway
Gong, B., Pan, Y., Zhao, W., Knable, L. A., Vempati, P., Begum, S., Ho, L., Wang, J., Yemul, S., Barnum, S. R., et al. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.06.016 · Cited by 41
A window into the brain: Tools to assess pre-clinical efficacy of biomaterials-based therapies on central nervous system disorders
Samal, J., Rebelo, A. L., & Pandit, A. S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.012 · Cited by 43
Sex‐specific accelerated decay in time/activity‐dependent plasticity and associative memory in an animal model of Alzheimer's disease
Navakkode, S., Gaunt, J. R., Pavón, M. V., Bansal, V. A., Abraham, R. P., Chong, Y. S., Ch’ng, T. H., & Sajikumar, S. (2021) · Aging Cell · doi:10.1111/acel.13502 · Cited by 43
The Roles of Phosphodiesterase 2 in the Central Nervous and Peripheral Systems
Zhang, C., Yu, Y., Ruan, L., Wang, C., Pan, J., Klabnik, J., Lueptow, L. M., Zhang, H., O’Donnell, J. M., & Xu, Y. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140826115245 · Cited by 40
“While PDE2 inhibition has been shown to be beneficial for enhancement of memory via cAMP/PKA/CREB/BDNF signaling [97], there is a vast array of other physiological stimuli that can alter the concentration of CREB.”
Background
Rolipram-induced improvement of cognitive function correlates with changes in hippocampal CREB phosphorylation, BDNF and Arc protein levels
Zhong, Y., Zhu, Y., He, T., Li, W., Yan, H., & Miao, Y. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.09.023 · Cited by 39
Chronically increased Gsα signaling disrupts associative and spatial learningPreprint
Bourtchouladze, R., Patterson, S. L., Kelly, M. P., Kreibich, A. S., Kandel, E. R., & Abel, T. G. (2006) · Learning & Memory · doi:10.1101/lm.354106 · Cited by 42
“Pharmacological experiments in mice have explored the effects of amplifying the cAMP pathway using the type IV-specific PDE inhibitor rolipram (Barad et al. 1998; Bourtchouladze et al. 2003; Tully et al. 2003; Alarcon et al. 2004; Gong et al. 2004).”
Method
The phosphodiesterase-4 inhibitor rolipram attenuates heroin-seeking behavior induced by cues or heroin priming in rats
Lai, M., Zhu, H., Sun, A., Zhuang, D., Fu, D., Chen, W., Zhang, H., & Zhou, W. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000595 · Cited by 39
“…Zhang, 2004; Li et al., 2009; Zhang, 2009), memoryenhancing effects (Barad et al., 1998; Rutten et al., 2008; Rutten et al., 2009; Li et al., 2011), and reversal of various memory deficits (Imanishi et al., 1997; Zhang and O’Donnell, 2000; Gong et al., 2004; Cheng et al., 2010; Wang et al., 2012).”
Background
New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment
Brullo, C., Ricciarelli, R., Prickaerts, J., Arancio, O., Massa, M., Rotolo, C., Romussi, A., Rebosio, C., Marengo, B., Pronzato, M. A., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.018 · Cited by 41
Insight into Inhibitory Mechanism of PDE4D by Dietary Polyphenols Using Molecular Dynamics Simulations and Free Energy Calculations
Furlan, V., & Bren, U. (2021) · Biomolecules · doi:10.3390/biom11030479 · Cited by 39
“Furthermore, the potential applicability of rolipram in improving learning and memory performance is also experimentally supported [18,19].”
Effects of increasing CREB-dependent transcription on the storage and recall processes in a hippocampal CA1 microcircuit
Bianchi, D., Michele, P. D., Marchetti, C., Tirozzi, B., Cuomo, S., Marie, H., & Migliore, M. (2013) · Hippocampus · doi:10.1002/hipo.22212 · Cited by 39
“…results suggesting that boosting the CREB pathway improves hippocampal-dependent memory in healthy rodents and restores this type of memory in an AD mouse model (Barad et al., 1998; Gong et al., 2004; Monti et al., 2006; Restivo et al., 2008; Sekeres et al., 2010; Yui et al., 2011).”
BackgroundResultInfluential
Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease
Gulisano, W., Tropea, M. R., Arancio, O., Palmeri, A., & Puzzo, D. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.002 · Cited by 38
“This is consistent with previous observations indicating that higher doses of rolipram or sildenafil exerted a long-lasting cognitive-enhancing effect in animal models of AD (Gong et al., 2004; Puzzo et al., 2009).”
Influential
Effects of protein kinase A and G inhibitors on hippocampal cholinergic markers expressions in rolipram- and sildenafil-induced spatial memory improvement
Hosseini-Sharifabad, A., Ghahremani, M. H., Sabzevari, O., Naghdi, N., Abdollahi, M. R., Beyer, C., Bollen, E., Prickaerts, J., Roghani, A., & Sharifzadeh, M. S. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.01.017 · Cited by 38
“Both cAMP and cGMP signaling pathways have been reported to be disrupted in Alzheimer's disease (AD) (Gong et al., 2004; Puzzo et al., 2009).”
Background
RETRACTED: Beneficial effects of asiaticoside on cognitive deficits in senescence-accelerated mice
Lin, X., Huang, R., Zhang, S., Wei, L., Zhuo, L., Wu, X., Tang, A., & Huang, Q. (2013) · Fitoterapia · doi:10.1016/j.fitote.2013.03.023 · Cited by 37
“Alzheimer's disease (AD), one of the most prevalent agedependent neurodegenerative disorders, is characterized by mild cognitive impairment at its onset followed by irreversible neuronal degeneration and dementia in later stages [1].”
Background
Retracted
Efficacy of phosphodiesterase‐4 inhibitors in juvenile Batten disease (CLN3)
Aldrich, A. L., Bosch, M. E., Fallet, R. W., Odvody, J., Burkovetskaya, M. E., Rao, K. V. R., Cooper, J. D., Drack, A. V., & Kielian, T. (2016) · Annals of Neurology · doi:10.1002/ana.24815 · Cited by 37
Design and Synthesis of Neuroprotective Methylthiazoles and Modification as NO-Chimeras for Neurodegenerative Therapy
Qin, Z., Luo, J., VandeVrede, L. A., Tavassoli, E., Fà, M., Teich, A. F., Arancio, O., & Thatcher, G. R. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300353r · Cited by 37
Mutant Presenilin 1 Alters Synaptic Transmission in Cultured Hippocampal Neurons
Priller, C., Dewachter, I., Vassallo, N., Paluch, S., Pace, C., Kretzschmar, H. A., LEUVEN, F. V., & Herms, J. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605066200 · Cited by 37
Modulating Neuroinflammation as a Prospective Therapeutic Target in Alzheimer’s Disease
Lee, E., & Chang, Y. (2025) · Cells · doi:10.3390/cells14030168 · Cited by 39
“This protective effect was confirmed to be associated with activating the PKA/CREB signaling pathway [291].”
Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline
Schaler, A. W., & Myeku, N. (2017) · Translational research · doi:10.1016/j.trsl.2017.11.004 · Cited by 34
“Accumulating evidence from several animal models indicates that PDE inhibitors show cognitive enhancing capacity.(25,42-49) In particular, cilostazol, an FDAapproved PDE3 inhibitor, has been shown to decrease amyloid beta accumulation and protect against betaamyloid-induced cognitive deficits in animal models.”
Background
Tau inhibits PKA by nuclear proteasome‐dependent PKAR2α elevation with suppressed CREB/GluA1 phosphorylation
Ye, J., Yin, Y., Liu, H., Fang, L., Tao, X., Wei, L., Zuo, Y., Yin, Y., Ke, D., & Wang, J. (2019) · Aging Cell · doi:10.1111/acel.13055 · Cited by 36
“The role of PKA on memory maintenance in different brain subset and pathologies is not always consistent, some researchers show that Aβ inhibits PKA, while acti vating PKA in hippocampus can improve cognitive functions (Gong et al., 2004; You et al., 2018).”
Background
Activation of Hippocampal CREB by Rolipram Partially Recovers Balance Between TNF-α and IL-10 Levels and Improves Cognitive Deficits in Diabetic Rats
Miao, Y., He, T., Zhu, Y., Wei, L., Wang, B., & Zhong, Y. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0209-3 · Cited by 36
“Long-term potentiation and phosphorylation of CREB in the hippocampus are enhanced by rolipram (Wang et al. 2012; Gong et al. 2004).”
Brain Region–Specific Decrease in the Activity and Expression of Protein Kinase A in the Frontal Cortex of Regressive Autism
Ji, L., Chauhan, V. P. S., Flory, M. J., & Chauhan, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023751 · Cited by 37
“PDE inhibitors such as rolipram could improve object recognition [38,39], passive avoidance [40,41], radial arm maze [40–42], Morris water maze [43], and contexual fear conditioning [30,43,44].”
Background
Calcium signaling in cognition and aging-dependent cognitive decline
Oliveira, A. M. M., & Bading, H. (2011) · BioFactors · doi:10.1002/biof.148 · Cited by 37
Traumatic Brain Injury Upregulates Phosphodiesterase Expression in the Hippocampus
Wilson, N. M., Titus, D. J., Oliva, A. A., Furones, C., & Atkins, C. M. (2016) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2016.00005 · Cited by 35
“…rolipram reverse learning and memory impairments in animal models of Alzheimer’s disease, psychosis, stress, and ischemia (Henkel-Tigges and Davis, 1990; Imanishi et al., 1997; Bach et al., 1999; Gong et al., 2004; Chen et al., 2010; Wiescholleck and Manahan-Vaughan, 2012; Sierksma et al., 2014).”
Background
Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease
Xi, M., Sun, T., Chai, S., Xie, M., Chen, S., Deng, L., Du, K., Shen, R., & Sun, H. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114170 · Cited by 34
Phosphodiesterase 4D and heart failure: a cautionary tale
Lehnart, S. E., & Marks, A. R. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.5.677 · Cited by 34
“Accordingly, selective PDE4 inhibitors are evaluated to treat asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, cognitive and inflammatory disorders and pulmonary hypertension [3,32,33,47-50].”
Background
Regulation of CRE-dependent transcription by presenilins: prospects for therapy of Alzheimer's disease
Beglopoulos, V., & Shen, J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.010 · Cited by 35
Aerobic exercise regulates GPR81 signal pathway and mediates complement- microglia axis homeostasis on synaptic protection in the early stage of Alzheimer's disease
Yang, J., Yuan, S., Jian, Y., Lei, Y., Hu, Z., Yang, Q., Yan, X., Zheng, L., Li, J.-H., & Liu, W. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122042 · Cited by 37
Histone deacetylase–mediated regulation of endolysosomal pH
Prasad, H., & Rao, R. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002025 · Cited by 35
“For example, rolipram, a PDE4 inhibitor that elevates cAMP levels, resulting in CREB activation, has shown efficacy as memory enhancer and for amelioration of A -related neuropathology in mouse models (57).”
Background
Alzheimer's disease pathogenesis: The role of disturbed sleep in attenuated brain plasticity and neurodegenerative processes
Havekes, R., Heckman, P. R. A., Wams, E. J., Stasiukonytė, N., Meerlo, P., & Eisel, U. L. M. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109420 · Cited by 35
Pathogenic Tau Causes a Toxic Depletion of Nuclear Calcium
Mahoney, R. E., Ochoa, E., Ramirez, P., Miller, H. E., Beckmann, A., Zuniga, G., Dobrowolski, R., & Frost, B. E. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107900 · Cited by 33
“…al., 2011), in primary hippocampal neurons from tau transgenic mice (Yin et al., 2016), and in β amyloid-based mouse models of Alzheimer’s disease (Gong et al., 2004; Pugazhenthi et al., 2011), no study to date has investigated nuclear Ca 2+ in the context of Alzheimer’s disease and related…”
Tranilast, a Transient Receptor Potential Vanilloid 2 Channel (TRPV2) Inhibitor Attenuates Amyloid β-Induced Cognitive Impairment: Possible Mechanisms
Thapak, P., Bishnoi, M., & Sharma, S. S. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-021-08675-x · Cited by 33
Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease
Savage, M. J., & Gingrich, D. E. (2009) · Drug Development Research · doi:10.1002/ddr.20287 · Cited by 33
“CaMKII, ERK, and PKA have been implicated as tau kinases and inhibition has been suggested, however, stimulation of these kinases reduces Ab production or may support processes of long term potentiation (LTP) and cognition in the face of increased Ab levels [Wang et al., 2008; Gong et al., 2004; Lisman et al., 2002; B…”
Phosphodiesterase: An Interface Connecting Cognitive Deficits to Neuropsychiatric and Neurodegenerative Diseases
Wang, Z., Zhang, Y., Zhang, H., & Li, Y. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140826115559 · Cited by 33
“In fact, it has been shown that the PDE1 inhibitor vinpocetine, the PDE2 inhibitor BAY 60-7550, the PDE4 inhibitor rolipram, the PDE5 inhibitor sildenafil, and the PDE9 inhibitor BAY 73-6691 can facilitate LTP processes [57, 165, 178 209, 270-273].”
Background
Neocortical plasticity deficits in fetal alcohol spectrum disorders: Lessons from barrel and visual cortex
Medina, A. E., & Krahe, T. E. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21447 · Cited by 32
“…has been shown to lower the threshold for inducing hippocampal long-term potentiation (LTP; Otmakhov et al., 2004), to restore its duration in aged mice (Barad et al., 1998) and to restore LTP in a transgenic model of Alzheimer’s disease (Gong et al., 2004).”
Background
Translocation of PKC by Yessotoxin in an in Vitro Model of Alzheimer’s Disease with Improvement of Tau and β-Amyloid Pathology
Alonso, E., Vale, C., Vieytes, M. R., & Botana, L. M. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400018y · Cited by 31
Downregulation of Wnt/β-catenin signaling causes degeneration of hippocampal neurons in vivo
Kim, H., Won, S., Hwang, D. Y., Lee, J.-S., Kim, M., Kim, R., Kim, W., Cha, B., Kim, T., Kim, D., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.013 · Cited by 31
Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington’s disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway
Saroj, P., Bansal, Y., Singh, R., Akhtar, A., Sodhi, R. K., Bishnoi, M., Sah, S. P., & Kuhad, A. (2021) · Inflammopharmacology · doi:10.1007/s10787-020-00787-3 · Cited by 32
Cognitive enhancers: Focus on modulatory signaling influencing memory consolidation
Roesler, R., & Schröder, N. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.028 · Cited by 31
Phosphodiesterase Inhibitors as Therapeutics for Traumatic Brain Injury
Titus, D. J., Oliva, A. A., Wilson, N., & Atkins, C. M. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140826113731 · Cited by 31
“Together, and results from other models such as Alzheimer’s disease and psychosis, supports the premise that PDE4 inhibition is a promising therapeutic target for cognitive enhancement [62, 154].”
Result
Efficacy of Selective PDE4D Negative Allosteric Modulators in the Object Retrieval Task in Female Cynomolgus Monkeys (Macaca fascicularis)
Sutcliffe, J. S., Beaumont, V., Watson, J. M., Chew, C. S., Beconi, M. G., Hutcheson, D. M., Dominguez, C., & Muñoz-Sanjuán, I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102449 · Cited by 31
Neuroprotective Effect of 2-Aminoethoxydiphenyl Borate (2-APB) in Amyloid β-Induced Memory Dysfunction: A Mechanistic Study
Thapak, P., Khare, P., Bishnoi, M., & Sharma, S. S. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-01012-z · Cited by 30
L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition
Huang, Z., Dias, R., Jones, T. R., Liu, S., Styhler, A., Claveau, D., Otu, F., Ng, K., Laliberté, F., Zhang, L., et al. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.03.010 · Cited by 30
From Age-Related Cognitive Decline to Alzheimer’s Disease: A Translational Overview of the Potential Role for Phosphodiesterases
Heckman, P. R. A., Blokland, A., & Prickaerts, J. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-58811-7_6 · Cited by 30
Neuroprotection and Neurodegenerative Diseases
Akwa, Y., Allain, H., Bentué‐Ferrer, D., Berr, C., Bordet, R., Geerts, H., Nieoullon, A. L., Onteniente, B., & Vercelletto, M. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000189053.25817.d6 · Cited by 32
Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimer’s Disease
Ettcheto, M., Abad, S., Petrov, D., Pedrós, I., Busquets, O., Sánchez‐López, E., Casadesús, G., Beas‐Zárate, C., Carro, E., Auladell, C., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0690-4 · Cited by 28
Flies as the ointment: Drosophila modeling to enhance drug discovery
Bell, A. J., McBride, S. M. J., & Dockendorff, T. C. (2009) · Fly · doi:10.4161/fly.3.1.7774 · Cited by 30
Insight into the phosphodiesterase mechanism from combined QM/MM free energy simulations
Wong, K. Y., & Gao, J. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08187.x · Cited by 29
Critical evaluation of current Alzheimer’s drug discovery (2018–19) & futuristic Alzheimer drug model approach
Dorababu, A. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103299 · Cited by 28
“22) were reported as PDE4 inhibitors [44].”
Ultrastructural and transcriptional profiling of neuropathological misregulation of CREB function
Valor, L. M., Jancic, D., Lujan, R., & Barco, A. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2010.40 · Cited by 28
The APP-interacting protein FE65 is required for hippocampus-dependent learning and long-term potentiationPreprint
Wang, Y., Zhang, M., Moon, C., Hu, Q., Wang, B., Martin, G. M., Sun, Z. S., & Wang, H. (2009) · Learning & Memory · doi:10.1101/lm.1499309 · Cited by 28
“Interestingly, rolipram treatment rescues memory deficits in a mouse model for AD (Gong et al. 2004).”
Background
Signalling Pathways Implicated in Alzheimer′s Disease Neurodegeneration in Individuals with and without Down Syndrome
Martínez‐Cué, C., & Rueda, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186906 · Cited by 26
Cilostazol improves hippocampus-dependent long-term memory in mice
Yanai, S., Semba, Y., Ito, H., & Endo, S. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3442-4 · Cited by 28
“2004), PDE4 (rolipram; Bach et al. 1999; Gong et al. 2004; Monti et al. 2006; Nagakura et al. 2002; Rutten et al. 2007), PDE5 (sildenafil; Boccia et al.”
Influential
Cyclic adenosine monophosphate as an endogenous modulator of the amyloid‐β precursor protein metabolism
Canepa, E., Domenicotti, C., Marengo, B., Passalacqua, M., Marinari, U. M., Pronzato, M. A., Fedele, E., & Ricciarelli, R. (2013) · IUBMB Life · doi:10.1002/iub.1109 · Cited by 27
Evaluating the protective effect of etazolate on memory impairment, anxiety- and depression-like behaviors induced by post traumatic stress disorder
Alzoubi, K. H., Subeh, Z. Y. A., & Khabour, O. F. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.10.012 · Cited by 27
Calpain‐mediated cleavage of DARPP ‐32 in A lzheimer's disease
Cho, K., Cho, M., Seo, J., Peak, J., Kong, K., Yoon, S., & Kim, D. (2015) · Aging Cell · doi:10.1111/acel.12374 · Cited by 26
“A disturbance in CREB function has been suggested to cause memory loss in AD brains and AD animal models (Yamamoto-Sasaki et al., 1999; Gong et al., 2004; Puzzo et al., 2005).”
Background
Early postnatal handling reduces hippocampal amyloid plaque formation and enhances cognitive performance in APPswe/PS1dE9 mice at middle age
Lesuis, S. L., van Hoek, B. A. C. E., Lucassen, P. J., & Krugers, H. J. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.05.016 · Cited by 27
“Previous studies using different behavioural tests in AD mouse models have indeed shown that these memory domains are particularly impaired (Gong et al., 2004; Lovasic, Bauschke, & Janus, 2005).”
Result
The Traditional Japanese Herbal Medicine Hachimijiogan Elicits Neurite Outgrowth Effects in PC12 Cells and Improves Cognitive in AD Model Rats via Phosphorylation of CREB
Kubota, K., Fukue, H., Sato, H., Hashimoto, K., Fujikane, A., Moriyama, H., Watanabe, T., Katsurabayashi, S., Kainuma, M., & Iwasaki, K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00850 · Cited by 25
“It has also been reported that accumulation of Aβ may lead to reduced CREB phosphorylation (Vitolo et al., 2002), while CREB-induced gene expression is impaired in both AD model mice and the brains of patients with AD (Phillips et al., 1991; Gong et al., 2004).”
Background
Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update
Khan, S. S., Khatik, G. L., & Datusalia, A. K. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411083922 · Cited by 25
“Phosphodiesterase type-4 inhibitor enhances LTP formation by increasing the level of c-AMP and enhancing the cAMP/PKA/CREB pathway [83].”
Activation of TGR5 Ameliorates Streptozotocin‐Induced Cognitive Impairment by Modulating Apoptosis, Neurogenesis, and Neuronal Firing
Mu, R.-H., Wu, X. G., Yuan, D., Zhao, J., Tang, S., Hong, H., & Long, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3716609 · Cited by 25
“Impor-tantly, agents with potential therapeutic worth for AD often have enhancing e ﬀ ects on the CREB-BDNF pathway [84].”
Methylxanthine reversal of opioid-evoked inspiratory depression via phosphodiesterase-4 blockade
Ruangkittisakul, A., & Ballanyi, K. (2010) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2010.04.025 · Cited by 25
Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer’s disease
Armstrong, P., Güngör, H., Anongjanya, P., Tweedy, C., Parkin, E. T., Johnston, J., Carr, I., Dawson, N., & Clapcote, S. J. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01852-z · Cited by 25
“Rolipram had no effect on A β peptide levels or plaque load in the PS/APP and Tg2576 strains [20, 21], although treatment over 24 days was shown to decrease A β peptide levels in brain tissue from 11-month-old 3xTg-AD mice [22].”
BackgroundMethodInfluential
Interactive effects of a protein kinase AII inhibitor and testosterone on spatial learning in the Morris water maze
Khorshidahmad, T., Tabrizian, K., Vakilzadeh, G., Nikbin, P., Moradi, S., Hosseini-Sharifabad, A., Roghani, A., Naghdi, N., & Sharifzadeh, M. S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.12.028 · Cited by 24
Biochemical evidence on positive effects of rolipram a phosphodiesterase-4 inhibitor in malathion-induced toxic stress in rat blood and brain mitochondria
Rezvanfar, M. A., Rezvanfar, M. A., Ranjbar, A., Baeeri, M., Mohammadirad, A., & Abdollahi, M. R. (2010) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2010.06.001 · Cited by 24
“been described in several models of neurological disorders, both acute and chronic [73–76].”
Background
Phosphodiesterase 4 inhibitor activates AMPK-SIRT6 pathway to prevent aging-related adipose deposition induced by metabolic disorder
Wang, Z., Liang, Y., Zhang, L., Zhang, N., Liu, Q., & Wang, Z. (2018) · Aging · doi:10.18632/aging.101559 · Cited by 24
“Although much has been learned about the potential benefits of PDE4 inhibitors in the treatment of agingrelated diseases such as Alzheimer's disease [7, 8, 19], relatively little is known about their effects on adipose deposition and metabolic disorders during aging.”
Background
PKA-CREB Signaling Suppresses Tau Transcription
Liu, H., Jin, X., Yin, X., Jin, N., Liu, F., & Qian, W. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142610 · Cited by 25
Amyloid β: Walking on the dark side of the moon
Fedele, E., Rivera, D., Marengo, B., Pronzato, M. A., & Ricciarelli, R. (2015) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.09.001 · Cited by 23
“The impairment of PKA/CREB activity has been observed in the brain of AD patients and AD animal models (Gong et al., 2004; Liang et al., 2007; Yamamoto-Sasaki et al., 1999), thus leading to the hypothesis that cAMP-enhancing strategies may be ben ficial for the treatment of memory loss in AD and…”
Background
Analysis of Age-Dependent Alterations in Excitability Properties of CA1 Pyramidal Neurons in an APPPS1 Model of Alzheimer’s Disease
Vitale, P., Pereira, A. R. S., Lupaşcu, C. A., Willem, M., Migliore, R., Migliore, M., & Marie, H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.668948 · Cited by 26
Accumulation of carboxy-terminal fragments of APP increases phosphodiesterase 8B.
Kametani, F., & Haga, S. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.029 · Cited by 23
“The effectiveness of repeated administration of PDE3 inhibitor (cilostazol), PDE4 inhibitor (rolipram or GEBR-7b), PDE5 inhibitor (sildenafil or tadalafil), PDE7 inhibitor (S14), and PDE9A inhibitor (BAY 73e6691) has been demonstrated in several model animals of AD (Bruno et al., 2011; Cheng et al., 2010; García-Barro…”
Background
Moderate treadmill exercise improves spatial learning and memory deficits possibly via changing PDE-5, IL-1 β and pCREB expression
Sabouri, M., Kordi, M. R., Shabkhiz, F., Taghibeikzadehbadr, P., & Geramian, Z. S. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111056 · Cited by 22
Novel Synthetic Coumarin‐Chalcone Derivative (E)‐3‐(3‐(4‐(Dimethylamino)Phenyl)Acryloyl)‐4‐Hydroxy‐2H‐Chromen‐2‐One Activates CREB‐Mediated Neuroprotection in Aβ and Tau Cell Models of Alzheimer’s Disease
Chiu, Y., Lin, T., Chen, C., Lin, C., Teng, Y.-S., Lin, C., Sun, Y., Hsieh‐Li, H. M., Su, M., Lee‐Chen, G., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3058861 · Cited by 22
“The cognitive function of presenilin 1 (PS1)/APP transgenic mice is significantly improved by increasing CREB phosphorylation with phosphodiesterase inhibitors [18, 19].”
Background
cAMP-Inhibits Cytoplasmic Phospholipase A2 and Protects Neurons against Amyloid-β-Induced Synapse Damage
Bate, C., & Williams, A. (2015) · Biology · doi:10.3390/biology4030591 · Cited by 22
Xanthoceraside prevented synaptic loss and reversed learning-memory deficits in APP/PS1 transgenic mice
Jin, G., Zhu, L., Liu, P., Xu, Q., Qi, Y. A., Zhou, X., Xu, J., Ji, X., Chi, T., & Zou, L. (2019) · The Journal of Physiological Sciences · doi:10.1007/s12576-019-00664-x · Cited by 22
Roflumilast protects against spatial memory impairments and exerts anti‐inflammatory effects after transient global cerebral ischemia
Bonato, J. M., Meyer, E., de Mendonça, P. S. B., Milani, H., Prickaerts, J., & de Oliveira, R. M. W. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.15089 · Cited by 22
“The pharmacological effects of PDE4 inhibitors in the central nervous system have been demonstrated to be dependent on molecular mechanisms underlying synaptic plasticity (Gong et al., 2004; Soares et al., 2016; Wiescholleck & Manahan-Vaughan, 2012).”
Background
A novel diol-derivative of chalcone produced by bioconversion, 3-(2,3-dihydroxyphenyl)-1-phenylpropan-1-one, activates PKA/MEK/ERK signaling and antagonizes Aβ-inhibition of the cascade in cultured rat CNS neurons
Rahim, M. A., Nakajima, A., Misawa, N., Shindo, K., Adachi, K., Shizuri, Y., Ohizumi, Y., & Yamakuni, T. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.09.046 · Cited by 21
The Role of Protein Kinase A in Anxiety Behaviors
Keil, M. F., Briassoulis, G. C., & Stratakis, C. A. (2016) · Neuroendocrinology · doi:10.1159/000444880 · Cited by 21
Zaprinast and Rolipram Enhances Spatial and Emotional Memory in the Elevated Plus Maze and Passive Avoidance Tests and Diminishes Exploratory Activity in Naive Mice
Akar, F., Mutlu, O., Celikyurt, I. K., Ulak, G., Erden, F., Bektaş, E., & Tanyerı, P. (2014) · Medical science monitor basic research/Medical science monitor. Basic research · doi:10.12659/msmbr.891149 · Cited by 20
A Biphasic and Brain-Region Selective Down-Regulation of Cyclic Adenosine Monophosphate Concentrations Supports Object Recognition in the Rat
Hotte, M., Dauphin, F., Fréret, T., Boulouard, M., & Levallet, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032244 · Cited by 22
“In fact, several studies have already reported a positive effect of PDE4 inhibition on spatial memory [3,5,33–37], inhibitory avoidance learning [5,33,38], contextual fear conditioning [4,39], and object recognition [40–42].”
Background
Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors
Brullo, C., Massa, M., Villa, C., Ricciarelli, R., Rivera, D., Pronzato, M. A., Fedele, E., Barocelli, E., Bertoni, S., Flammini, L., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.027 · Cited by 20
Synthesis, Biological Evaluation, and Molecular Modeling of New 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-Dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) Related Phosphodiesterase 4D (PDE4D) Inhibitors
Brullo, C., Massa, M., Rocca, M., Rotolo, C., Guariento, S., Rivera, D., Ricciarelli, R., Fedele, E., Fossa, P., & Bruno, O. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500855w · Cited by 20
Phosphodiesterase Inhibition to Target the Synaptic Dysfunction in Alzheimer’s Disease
Bales, K. R., Plath, N., Svenstrup, N., & Menniti, F. S. (2010) · Topics in medicinal chemistry · doi:10.1007/7355_2010_8 · Cited by 22
“LTP deficits are also observed in slices prepared from transgenic mice that overexpress Ab [90].”
Background
Changes in NMDA receptor-induced cyclic nucleotide synthesis regulate the age-dependent increase in PDE4A expression in primary cortical cultures
HajjHussein, H., Suvarna, N. U., Gremillion, C., Chandler, L. J., & O’Donnell, J. M. (2007) · Brain Research · doi:10.1016/j.brainres.2007.02.090 · Cited by 20
“…PDE4, and PDE2 have been implicated in hippocampal-LTP and memory performance (Bevilaqua et al., 2005; Boess, 2004; Chien et al., 2003; 2005; Gong et al., 2004; Liauw et al., 2005; Lu et al., 1999; Nicoll and Malenka, 1999; Roberson and Sweatt, 1996; Vianna et al., 2000; Wong et al., 1999;…”
Background
Restoration of Mitochondrial Dysfunction in 6-Hydroxydopamine Induced Parkinson’s disease: a Complete Review
Mehan, S., Kaur, G., Dudi, R., Rajput, M., & Kalra, S. (2017) · Open Journal of Parkinson s Disease and Treatment · doi:10.17352/ojpdt.000001 · Cited by 19
“Moreover, increase level of cAMP involved in the inhibition of apoptotic and necrotic cell death leads to improvement in cognitive functioning [52-61].”
Background
Improvement of cognitive function in wild-type and Alzheimer´s disease mouse models by the immunomodulatory properties of menthol inhalation or by depletion of T regulatory cells
Casares, N., Alfaro, M., Cuadrado‐Tejedor, M., Lasarte-Cía, A., Navarro, F. C., Vivas, I., Espelosin, M., Cartas‐Cejudo, P., Fernández‐Irigoyen, J., Santamaría, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130044 · Cited by 20
Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia
Siuciak, J. A., & Strick, C. A. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.7.1001 · Cited by 19
Phosphodiesterase-4 inhibition restored hippocampal long term potentiation after primary blast
Vogel, E. W., Morales, F. N., Meaney, D. F., Bass, C. R., & Morrison, B. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.03.025 · Cited by 23
“…was effective in improving outcome in someexperimentalmodels of TBI and also reduced cognitive impairments associated with Alzhemer's disease, schizophrenia and aging (Gong et al., 2004; Maxwell et al., 2004; Smith et al., 2009; Titus et al., 2014; Wiescholleck and Manahan-Vaughan, 2012).”
Background
AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy
Borreca, A., Latina, V., Corsetti, V., Middei, S., Piccinin, S., Valle, F. D., Bussani, R., Ammassari‐Teule, M., Nisticò, R., Calissano, P., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0974-3 · Cited by 18
Pharmacokinetics and pharmacodynamics of nitric oxide mimetic agents
Horton, A., & Schiefer, I. T. (2019) · Nitric Oxide · doi:10.1016/j.niox.2019.01.001 · Cited by 19
Ameliorative role of rolipram, PDE-4 inhibitor, against sodium arsenite–induced vascular dementia in rats
Virk, D., Kumar, A., Jaggi, A. S., & Singh, N. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-15189-3 · Cited by 19
“Rolipram (0.03 and 0.06 mg/kg body weight) (Zhang and O’Donnell 2000; Gong et al. 2004; Akar et al. 2015) was administered intraperitoneally (i.p.) whereas sodium arsenite (SA) (5 mg/kg body weight) (El-Demerdash et al. 2009) and donepezil (0.5mg/kg body weight) (Gawel et al. 2014) were…”
BackgroundMethodInfluential
Novel Therapies for Parkinsonian Syndromes–Recent Progress and Future Perspectives
Przewodowska, D., Marzec, W. Z., & Madetko‐Alster, N. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.720220 · Cited by 20
X-linked mental retardation and epigenetics
Froyen, G., Bauters, M., Voet, T., & Marynen, P. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00526.x · Cited by 19
“βΑ deposits impair phosphorylation of CREB [89] and this can be restored in vivo [90, 91].”
Background
Deficits in object-in-place but not relative recency performance in the APPswe/PS1dE9 mouse model of Alzheimer’s disease: Implications for object recognition
Bonardi, C., Pardon, M., & Armstrong, P. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.07.008 · Cited by 17
Selective inhibitors of phosphodiesterases: therapeutic promise for neurodegenerative disorders
Umar, T., & Hoda, N. (2015) · MedChemComm · doi:10.1039/c5md00419e · Cited by 18
Neuroprotective effect of roflumilast under cerebral ischaemia/reperfusion injury in juvenile rats through NLRP‐mediated inflammatory response inhibition
Keskin, H., Keskin, F., Tavacı, T., Halıcı, H., Yüksel, T. N., Özkaraca, M., Bilen, A., & Halıcı, Z. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13493 · Cited by 18
Reduction of autophagy markers mediated protective effects of JNK inhibitor and bucladesine on memory deficit induced by Aβ in rats
Mohammadi, M., Guan, J., Khodagholi, F., Yans, A., Khalaj, S., Gholami, M., Taghizadeh, G., Aliaghaei, A., Abdollahi, M. R., Ghahremani, M., et al. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1222-x · Cited by 18
Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement
Wei, X., Yu, G., Shen, H., Luo, Y., Shang, T., Shen, R., Xi, M., & Sun, H. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106278 · Cited by 17

Authors: Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O.
Affiliations: Nathan Kline Institute for Psychiatric Research (US)
Columbia University (US)
ORCID: Gong, Bing
Vitolo, Ottavio V.
Trinchese, Fabrizio
Liu, Shumin
Shelanski, Michael
Arancio, Ottavio
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2004-12-01
Volume: 114
Issue: 11
Pages: 1624-1634
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci22831
PMC: PMC529285
OpenAlex: W2034986487
Cited by: 442
References: 60
Citations by year: 2026: 12 · 2025: 14 · 2024: 16 · 2023: 15 · 2022: 11 · 2021: 13 · 2020: 21 · 2019: 20 · 2018: 17 · 2017: 33 · 2016: 17 · 2015: 20 · 2014: 28 · 2013: 23 · 2012: 23
FWCI: 12.13
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Alzheimer's Association
University of Minnesota
York University
National Institutes of Health
School of Medicine, New York University
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Alzheimer's disease, rolipram, amyloid-beta 42, synaptic plasticity, long-term potentiation, contextual learning, memory impairment, phosphodiesterase-4 inhibitors, cAMP/PKA/CREB signaling, synaptic transmission, APP/PS1 double transgenic mice
MeSH terms: Alzheimer Disease, Animals, Cognition, Disease Models, Animal, Hippocampus, Humans, Learning, Male, Membrane Proteins, Mice, Transgenic, Synaptic Transmission, Phosphodiesterase Inhibitors, Amyloid beta-Protein Precursor, Cyclic AMP Response Element-Binding Protein, Long-Term Potentiation, Rolipram, Mice, Presenilin-1, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks